title: Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression.
abstract: Formononetin has shown a variety of pharmacologic properties including anti-inflammatory effect. In the present study, we analyzed the role of formononetin in acute lung injury induced by lipopolysaccharide (LPS) in mice. The cell counting in the bronchoalveolar lavage fluid (BALF) was measured. The animal lung edema degree was evaluated by wet/dry weight ratio. The superoxidase dismutase (SOD) activity and myeloperoxidase (MPO) activity was assayed by SOD and MPO kits, respectively. The levels of inflammatory mediators, tumor necrosis factor-α (TNF-α) and IL-6,were assayed by enzyme-linked immunosorbent assay method. Pathological changes of hung tissues were observed by HE staining. Peroxisome proliferator-activated receptor (PPAR)-γ gene expression was measured by real-time PCR. The data showed that treatment with the formononetin group markedly attenuated inflammatory cell numbers in the BALF, increased PPAR-γ gene expression and improved SOD activity and inhibited MPO activity. The histological changes of the lungs were also significantly improved by formononetin compared to LPS group. The results indicated that formononetin has a protective effect on LPS-induced acute lung injury in mice.
authors.affiliation: Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Tongjiaxiang 24, Nanjing, Jiangsu, 210009, People's Republic of China, mazhanqiang0427@163.com.
authors.forename: Zhanqiang
authors.initials: Z
authors.lastname: Ma
authors.forename: Weiwei
authors.initials: W
authors.lastname: Ji
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.forename: Shiping
authors.initials: S
authors.lastname: Ma
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D004195:Disease Models, Animal; D004487:Edema / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D015850:Interleukin-6 / Q000378:metabolism; D007529:Isoflavones / Q000627:therapeutic use*; D008070:Lipopolysaccharides; D008168:Lung / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D047495:PPAR gamma / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D048789:Phytoestrogens / Q000627:therapeutic use*; D011654:Pulmonary Edema / Q000188:drug therapy / Q000276:immunology; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D007529:Isoflavones; D008070:Lipopolysaccharides; D047495:PPAR gamma; D048789:Phytoestrogens; D014409:Tumor Necrosis Factor-alpha; C007768:formononetin; D009195:Peroxidase; D013482:Superoxide Dismutase
references.citation: J Intensive Care Med. 2006 May-Jun;21(3):119-43
references.pmid: 16672636
references.citation: PPAR Res. 2008;2008:328172
references.pmid: 18288284
references.citation: Endocr Rev. 1999 Oct;20(5):649-88
references.pmid: 10529898
references.citation: Crit Care Med. 2003 Apr;31(4 Suppl):S195-9
references.pmid: 12682440
references.citation: N Engl J Med. 1995 Jan 5;332(1):27-37
references.pmid: 7646623
references.citation: Annu Rev Med. 2002;53:409-35
references.pmid: 11818483
references.citation: Am J Pathol. 2002 Dec;161(6):2219-28
references.pmid: 12466136
references.citation: J Cardiovasc Risk. 2001 Aug;8(4):187-94
references.pmid: 11550996
references.citation: Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1487-94
references.pmid: 11704601
references.citation: J Leukoc Biol. 2005 May;77(5):598-625
references.pmid: 15689384
references.citation: Int Immunopharmacol. 2010 Apr;10(4):406-11
references.pmid: 20074667
references.citation: Crit Care Med. 2003 Apr;31(4 Suppl):S276-84
references.pmid: 12682453
references.citation: J Immunol. 2006 Mar 1;176(5):3189-95
references.pmid: 16493079
references.citation: Nat Immunol. 2004 Jan;5(1):104-12
references.pmid: 14691478
references.citation: Expert Rev Respir Med. 2010 Dec;4(6):773-83
references.pmid: 21128752
references.citation: Altern Med Rev. 1998 Oct;3(5):338-44
references.pmid: 9802911
references.citation: Am Rev Respir Dis. 1987 Jul;136(1):19-28
references.pmid: 3300442
references.citation: Respir Physiol Neurobiol. 2009 Oct 31;169(1):36-43
references.pmid: 19686870
references.citation: Pediatr Pulmonol. 2006 Jan;41(1):23-34
references.pmid: 16267824
references.citation: Circ Res. 2003 May 30;92(10):1162-9
references.pmid: 12714563
references.citation: Altern Med Rev. 1998 Dec;3(6):422-31
references.pmid: 9855567
references.citation: Nat Med. 2001 Jan;7(1):48-52
references.pmid: 11135615
references.citation: Science. 2003 Oct 17;302(5644):453-7
references.pmid: 12970571